NCT05543629

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

A Phase 1b/2 Study of BMS-986442 in Combination With Nivolumab or Nivolumab and Chemotherapies in Participants With Advanced Solid Tumors and Non-small Cell Lung Cancer

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.

Conditions

• Advanced Solid Tumors
• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
BIOLOGICAL	BMS-986442	Specified dose on specified days
BIOLOGICAL	Nivolumab	Specified dose on specified days
DRUG	Docetaxel	Specified dose on specified days
DRUG	Carboplatin	Specified dose on specified days
DRUG	Pemexetred	Specified dose on specified days
DRUG	Paclitaxel	Specified dose on specified days

Timeline

• Start date: 2022-10-04
• Primary completion: 2024-09-12
• Completion: 2024-09-12
• First posted: 2022-09-16
• Last updated: 2025-03-18
• Results posted: 2025-03-18

Locations

32 sites across 5 countries: United States, Australia, Italy, Poland, Spain

Regulatory

• FDA-regulated drug study